Skip to content

The effect of propolis supplementation in treatment of non-alcoholic fatty liver

The effect of propolis and placebo supplements associated with weight loss diet on prooxidant-antioxidant balance, oxidative stress status, nutritional status, liver function and body composition in patients with non-alcoholic fatty liver

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20100209003320N20
Enrollment
46
Registered
2021-06-27
Start date
2021-07-06
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty live. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Patients in this group will receive a weight loss diet with propolis supplement (3 capsules of 500 mg per day) after each meal for 8 weeks. This supplement is provi

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: NAFLD (Grade 1 and 2) Age 20-50 years Body mass index(BMI) in the range of 30-40 Kg / m2 Willingness to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy, lactation and menopause in women Smoking and alcohol use Skin or gastrointestinal allergies to propolis, honey and any of the beehive products Adherence to a special diet three months before the study Consumption of chemical or herbal medicines for weight loss Taking antibiotics or various supplements that affect the levels of liver enzymes Performing weight loss surgery in the last year or strict weight loss diets in the last three months Suffering from any conditions affecting liver function Use of hepatotoxic medications Taking multivitamins or antioxidant supplements during the last 3 months

Design outcomes

Primary

MeasureTime frame
Pro-Oxidant Antioxidant Balance (PAB). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic_ colorimetric method and read it through ELISA.;Glutathione peroxidase(GPX). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Spectrophotometric method.;Superoxide dismutase (SOD). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Spectrophotometric method.;Malondialdehyde (MDA). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Spectrophotometric method.;Total Antioxidant Capacity (TAC). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Spectrophotometric method.;Fat mass. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Using bioelectric impedance analyzer.;Free fat mass. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Using bioelectric impedance analyzer.;Body water. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Using bioelectric impedance analyzer.;Intake of energy, macronutrients and antioxidant micronutrients. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: The intake by 3-days food record form and analysis using nutritionist 4 software.;Alanine aminotransferase. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic method.;Aspartate aminotransferase. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic method.;Gamma Glutamyl transferase. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic method.;Fatty liver grade. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Ultrasound findings.;Liver fibrosis score. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Liver fibrosis score formula.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehrangiz Ebrahimimamagani

Tabriz University of Medical Sciences

mebrahimimameghani@gmail.com+98 41 3334 1113

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026